Severe degenerative aortic stenosis with preserved ejection fraction does not change adipokines serum levels

• Published in: Cardiology journal Vol. 26; no. 5; pp. 483 - 492
• Main Authors: Mizia-Stec, Katarzyna, Bochenek, Tomasz, Kusz, Błażej, Mizia-Szubryt, Magdalena, Sikora-Puz, Agnieszka, Gieszczyk-Strózik, Klaudia
• Format: Journal Article
• Language: English
• Published: Poland Wydawnictwo Via Medica 06.11.2019; Via Medica
• Subjects: Adipokines - blood; Adiponectin - blood; Age; Aged; Aortic Valve Stenosis - blood; Aortic Valve Stenosis - diagnostic imaging; Aortic Valve Stenosis - physiopathology; Atherosclerosis; Biomarkers - blood; Body mass index; Cardiovascular disease; Case-Control Studies; Clinical Cardiology; Coronary Artery Disease - blood; Coronary Artery Disease - diagnostic imaging; Coronary Artery Disease - physiopathology; Cytokines - blood; Ejection fraction; Female; Humans; Leptin - blood; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase - blood; Prospective Studies; Resistin - blood; Severity of Illness Index; Stroke Volume; Vascular Remodeling; Ventricular Function, Left; atherosclerosis; adipokines; aortic stenosis; vascular remodeling; echocardiography
• ISSN: 1897-5593; 1898-018X; 1897-5593
• DOI: 10.5603/CJ.a2017.0135

The role of the adipokines in the pathogenesis of aortic stenosis (AS) is not well established. The aim was to evaluate the relationship between adipokines and clinical characteristics as well as echocardiographic indices and noninvasive markers of vascular remodeling in patients with severe AS with preserved ejection fraction (EF). Sixty-five patients (F/M: 38/27; age: 68.3 ± 9.0 years; body mass index [BMI]: 29.6 ± 4.3 kg/m2) with severe AS with preserved EF: 33 patients with paradoxical low-flow low-gradient AS (PLFLG AS) and 32 patients with normal flow high-gradient AS (NFHG AS) were prospectively enrolled into the study. Twenty-four subjects (F/M: 14/10; age: 65.4 ± 8.7 years; BMI: 29.6 ± 4.3 kg/m2) who matched as to age, sex, BMI and coronary artery disease (CAD) constituted the control group (CG). Clinical data and markers of vascular remodeling were related to the serum adipokines. There were no differences in the adipokines concentrations in the AS/CG. Patients with AS and coexisting CAD were characterized by decreased serum adiponectin (9.9 ± 5.5 vs. 12.7 ± 5.8 μg/mL, p = 0.040) and leptin (8.3 ± 7.8 vs. 21.6 ± 17.1 ng/mL, p < 0.001) levels compared to subjects without CAD. There were no differences in the serum adipokines concentrations between patients with PLFLG AS and NFHG AS. Systemic hypertension, diabetes, hyperlipidemia or markers of vascular remodeling did not discriminate adipokines concentrations. Multivariate regression analysis indicated that age (F = 3.02; p = 0.015) and E/E' index (F = 0.87, p = 0.032) were independent predictors of the adiponectin level in the AS group. The presence of AS with preserved EF did not change the adipokine serum profile. Adipokines levels were modified by coexisting atherosclerosis but not the typical cardiovascular risk factors or the hemodynamic type of AS.